Arboretum Ventures

Arboretum Ventures LLC is a venture capital firm based in Ann Arbor, Michigan, founded in 2002. The firm specializes in seed-stage, early-stage, mid-stage investments, and growth capital, primarily focusing on the healthcare sector. Its investment areas include medical devices, diagnostics, healthcare information technology, therapeutics, technology-based healthcare services, and life science tools. Arboretum Ventures aims to invest between $5 million and $15 million in companies across the United States, with a particular emphasis on the Midwest and Michigan. The firm is recognized for its commitment to fostering innovation within the healthcare industry.

Cheryl Brown

Financial Analyst

Robert Cesaro

Associate

Jan Garfinkle

Founder and Managing Partner

Sarah Jameson

Senior Associate

Dan Kidle

Partner

Marcy Marshall

CFO

Paul McCreadie

Partner and COO

Tim Petersen

Founder and Managing Partner

Thomas Shehab

Managing Partner

Nicole Walker

Managing Partner

Past deals in Michigan

Delphinus Medical Technologies

Series D in 2022
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

Navv Systems

Series A in 2022
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multiple U.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs.

Akadeum

Series B in 2021
Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, founded in 2014. The company specializes in manufacturing microbubble cell separation products designed to facilitate the removal of target cells from biological samples. Its product line includes T cell and B cell isolation kits for both human and mouse cells, as well as products for red blood cell depletion. Akadeum utilizes buoyancy-activated cell sorting technology, employing microscopic microbubbles that capture target cells and float them to the surface for efficient removal. This innovative approach enhances the efficiency of downstream testing and analysis for medical practitioners. The company's products are available for purchase online, and it maintains a strategic partnership with Agilent Technologies.

Navv Systems

Seed Round in 2021
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multiple U.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs.

Fifth Eye

Series A in 2019
Fifth Eye Inc. is a medical software company that specializes in developing real-time analytics systems for monitoring hemodynamic instability in patients. The company's innovative software continuously analyzes a patient's clinical data to provide early warnings of potential health issues, allowing healthcare professionals to intervene proactively. It delivers rapid assessments, with initial scoring in just five minutes, and offers continuous monitoring without the need for baseline data or integration with electronic health records. By utilizing advanced artificial intelligence and real-time ECG data, Fifth Eye's system enhances clinical decision-making, aiming to improve patient outcomes, prevent adverse events, and reduce hospital stays and costs. Founded in 2017 and based in Ann Arbor, Michigan, Fifth Eye was previously known as Trove Analytics, Inc., before rebranding in June 2018.

Strata Oncology

Series B in 2018
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Strata Oncology

Series A in 2016
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

ArborMetrix

Series B in 2016
ArborMetrix, Inc. is a data analytics and technology company focused on enhancing healthcare outcomes and advancing research through its innovative platform. Founded in 2011 and headquartered in Ann Arbor, Michigan, ArborMetrix offers a range of solutions for the healthcare industry, including data collection and integration, performance measurement, and analytics. Its products, such as EpisodeMetrix, provide critical insights into payer claims data, helping healthcare payers and at-risk providers manage costs and improve specialty care quality. The company also offers RegistryMetrix, which allows for the creation of specialized clinical registries, and SurgicalMetrix, which analyzes the performance of surgical groups by integrating clinical, financial, and operational data. ArborMetrix serves a diverse clientele that includes specialty societies, medical device manufacturers, pharmaceutical companies, and health systems, delivering actionable insights to optimize clinical outcomes and financial performance.

Delphinus Medical Technologies

Series C in 2015
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, founded in 2012. It specializes in developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. The company’s platform provides in-vitro testing tools that enhance the efficiency and cost-effectiveness of laboratory operations. By improving the capabilities of laboratory professionals, NeuMoDx aims to increase the adoption of molecular diagnostic testing among medical providers, facilitating earlier and more accurate disease identification and treatment. In 2013, NeuMoDx changed its name from Molecular Systems Corporation and has since become a subsidiary of QIAGEN N.V.

Delphinus Medical Technologies

Series B in 2013
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

ArborMetrix

Series B in 2013
ArborMetrix, Inc. is a data analytics and technology company focused on enhancing healthcare outcomes and advancing research through its innovative platform. Founded in 2011 and headquartered in Ann Arbor, Michigan, ArborMetrix offers a range of solutions for the healthcare industry, including data collection and integration, performance measurement, and analytics. Its products, such as EpisodeMetrix, provide critical insights into payer claims data, helping healthcare payers and at-risk providers manage costs and improve specialty care quality. The company also offers RegistryMetrix, which allows for the creation of specialized clinical registries, and SurgicalMetrix, which analyzes the performance of surgical groups by integrating clinical, financial, and operational data. ArborMetrix serves a diverse clientele that includes specialty societies, medical device manufacturers, pharmaceutical companies, and health systems, delivering actionable insights to optimize clinical outcomes and financial performance.

Fidelis SeniorCare

Series A in 2013
Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

Tangent Medical Technologies

Series B in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Hicuity Health

Series D in 2011
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Tangent Medical Technologies

Series A in 2011
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Delphinus Medical Technologies

Series A in 2010
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Hicuity Health

Series B in 2008
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Hicuity Health

Series A in 2006
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Asterand

Series C in 2003
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K., our employees focus on providing services and products to accelerate drug discovery research from target identification through compound evaluation and drug safety.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.